OmniAb (OABI) Cost of Revenue (2025 - 2026)
OmniAb (OABI) posted quarterly Cost of Revenue of $15000.0 for Q1 2026, up 400.0% year-over-year from $3000.0 in Q1 2025, and up 66.67% quarter-over-quarter from $9000.0 in Q4 2025.
Powered by 
Analysis
OmniAb (OABI) Cost of Revenue (2025 - 2026) Analysis & Trends
OmniAb (OABI) has reported Cost of Revenue for 2 consecutive years, with $15000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 400.0% year-over-year to $15000.0; the TTM figure through Mar 2026 stood at $315000.0 (up 10400.0% YoY), while the FY2025 annual figure was $303000.0, changed N/A from the prior year.
- Cost of Revenue rose to $15000.0 in Q1 2026 per OABI's latest filing, from $9000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $262000.0 in Q2 2025 and bottomed at $3000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 67.21 Mn |
| 10 | OmniAb | 571.75 Mn | 519.75 Mn | 12.81 Mn | 610,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 610,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 262,000.00 |
| Mar 31, 2025 | 3,000.00 |